Clinical efficacy of cyclosporin A Neoral in the treatment of paediatric lupus nephritis with heavy proteinuria

L. W. Fu, L. Y. Yang, W. P. Chen, C. Y. Lin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

94 Scopus citations

Abstract

Cyclosporin A (CsA) was introduced in recent years for the treatment of lupus nephritis in patients with steroid resistance or in those with severe corticosteroid toxicity. Our previous study on paediatric patients showed that Neoral (a new microemulsion formulation) had better bioavailability than CsA capsules. To evaluate the clinical efficacy of Neoral in children with lupus nephritis compared with conventional therapy, we performed an open randomized study on 40 children, ranging from 9 to 14 yr old, with class III-V lupus nephritis and heavy proteinuria. They were randomly assigned to either Neoral (5 mg/kg/day), administered q.12.h, or prednisolone (2 mg/kg/day) plus cyclophosphamide (2 mg/kg/day) for 1 yr. Both groups showed a significant decrease in proteinuria (Neoral: 4.62 ± 1.93 to 0.35 ± 0.29 g/day, P < 0.05; prednisolone plus cyclophosphamide: 4.52 ± 1.86 to 0.62 ± 0.21 g/day, P < 0.01). The CH50 haemolytic assay titre decreased after 1 yr of Neoral treatment (26.5 ± 0.9 to 21.4 ± 2.2 U/ml, P < 0.05). Serum C3 and anti-double-stranded (ds) DNA antibody levels also fell with Neoral (C3: 86.2 ± 6.8 to 76.3 ± 4.5 mg/dl; anti-ds DNA antibodies: 14.1 ± 3.2 to 8.2 ± 1.4 IU/ml, P < 0.05). The Neoral group had a significant increase in growth rate over the prednisolone plus cyclophosphamide group (8.2 ± 1.1 cm/yr vs 2.7 ± 0.6 cm/yr, P < 0.01) with improvement of growth status. During the study period, patients tolerated Neoral well with no significant changes in renal function, liver function or lipid profile. Our study implies that Neoral appears to be effective in suppressing proteinuria. Neoral should be regarded as being adjunctive therapy, perhaps with a steroid-sparing effect, in paediatric lupus nephritis. However, its long-term use awaits further studies.

Original languageEnglish
Pages (from-to)217-221
Number of pages5
JournalBritish Journal of Rheumatology
Volume37
Issue number2
DOIs
StatePublished - 1998

Keywords

  • Cyclosporin A
  • Heavy proteinuria
  • Lupus nephritis
  • Neoral

Fingerprint

Dive into the research topics of 'Clinical efficacy of cyclosporin A Neoral in the treatment of paediatric lupus nephritis with heavy proteinuria'. Together they form a unique fingerprint.

Cite this